|
GAPVD1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.15550000012732E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.85590000001401E-06 |
| Normal-vs-Stage2 |
4.022300E-03 |
| Normal-vs-Stage3 |
1.40259999947823E-07 |
| Normal-vs-Stage4 |
2.75349998357655E-09 |
| Stage1-vs-Stage2 |
4.575600E-01 |
| Stage1-vs-Stage3 |
1.139210E-01 |
| Stage1-vs-Stage4 |
2.085900E-02 |
| Stage2-vs-Stage3 |
9.910000E-02 |
| Stage2-vs-Stage4 |
1.956380E-02 |
| Stage3-vs-Stage4 |
3.302200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.56600000428875E-08 |
| Normal-vs-AfricanAmerican |
2.257800E-01 |
| Normal-vs-Asian |
2.70110000000212E-06 |
| Caucasian-vs-AfricanAmerican |
1.342780E-01 |
| Caucasian-vs-Asian |
9.867000E-01 |
| AfricanAmerican-vs-Asian |
1.557570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.74000000000107E-06 |
| Normal-vs-Female |
1.54860000045609E-07 |
| Male-vs-Female |
9.655200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.79393999999444E-05 |
| Normal-vs-Age(41-60Yrs) |
2.6054000001885E-07 |
| Normal-vs-Age(61-80Yrs) |
4.98729999998115E-06 |
| Normal-vs-Age(81-100Yrs) |
1.806060E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.148400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.851200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.291900E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.282200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.824400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.504800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.823080E-03 |
| Classical-VS-Follicular |
9.071200E-01 |
| Classical-VS-Other |
5.093600E-01 |
| Classical-VS-Normal |
2.03539999998892E-06 |
| Tall-VS-Follicular |
7.240000E-03 |
| Tall-VS-Other |
4.548400E-01 |
| Tall-VS-Normal |
9.84210002386021E-09 |
| Follicular-VS-Other |
5.256400E-01 |
| Follicular-VS-Normal |
1.993920E-04 |
| Other-VS-Normal |
7.041900E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.0350999999641E-06 |
| Normal-vs-N1 |
3.87489999975621E-07 |
| N0-vs-N1 |
1.092210E-01 |
|
|
